^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BRCA1 (Breast cancer 1, early onset)

    i
    Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset
    1d
    DUO-O: Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (clinicaltrials.gov)
    P3, N=1407, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Dec 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel
    1d
    Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer. (PubMed, J Exp Clin Cancer Res)
    Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • SLFN11 (Schlafen Family Member 11)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Lynparza (olaparib) • temozolomide • Zanosar (streptozocin)
    2d
    Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review. (PubMed, Gynecol Oncol Rep)
    Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Zejula (niraparib)
    2d
    Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). (PubMed, Cancer Innov)
    Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence-based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • AiRuiYi (fluzoparib)
    2d
    Germline testing, access to genetic counseling, and treatment implications in advanced breast cancer. (PubMed, Ann Med Surg (Lond))
    Supportive services such as counseling, support groups, and integrative therapy could assist patients and their families in overcoming emotional, social and spiritual needs. Besides treatment, clinical trials could enhance cancer research and lead to effective treatment.
    Journal • BRCA Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA1 mutation
    2d
    Clinicopathologic characteristics of early-onset breast cancer among unselected young Black women. (PubMed, Cancer)
    Among unselected young Black women with breast cancer, our findings demonstrate that the highest frequency of HBC GPVs are in BRCA1, BRCA2, and PALB2, with identification of distinct histopathologic and demographic characteristics across HBC genes, underscoring the critical need for genetic testing in all populations.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2)
    4d
    Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC). (PubMed, Oncologist)
    These data demonstrate clinical activity of niraparib in patients with metastatic or unresectable pancreatic cancers harboring DDR gene defects. Future studies are warranted to establish their roles in diverse genetic patient subpopulations.
    P2 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    Zejula (niraparib)
    5d
    STARTER: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative
    |
    capecitabine • Jiataile (sacituzumab tirumotecan)
    5d
    Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy. (PubMed, Front Oncol)
    As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur-gimeracil-oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer. Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Teysuno (gimeracil/oteracil/tegafur)
    5d
    Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors. (PubMed, NAR Cancer)
    By performing transient silencing experiments, we highlight PARP1-PARP2 trapping at replicative gaps as a major determinant of sensitivity to these compounds. Crucially, loss of 53BP1 does not rescue PARPi sensitivity in CHTF18 KO cells, outlining Polε and the CHTF18-RFC2/5 complex as potential novel targets for cancer therapeutics.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA2 mutation • BRCA1 mutation
    5d
    MK3475-A53: Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers (clinicaltrials.gov)
    P2, N=9, Completed, University of Colorado, Denver | Active, not recruiting --> Completed | Trial completion date: Dec 2028 --> Jan 2026
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • WRN (WRN RecQ Like Helicase) • FANCG (FA Complementation Group G) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    HRD
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    6d
    Prevalence of BRCA1 and BRCA2 Germline Mutations in Western Saudi Patients with Epithelial Tubo-Ovarian Carcinoma. (PubMed, Saudi Med J)
    We identified BRCA gene mutations in 38.6% of our patients. Most comparisons revealed no significant differences between BRCA-positive and BRCA-negative patients, highlighting the need for additional studies to determine the prognostic and clinical value of gene testing in EOC.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA mutation